Establishing dose response relationships is foundational in drug development. To improve confidence in a development program, understanding dose response in animals and how that translates to early clinical development studies is critical. Traditional approaches to predict clinical doses that achieve minimal biological activity and maintain wide safety margins may not apply to gene therapy (GT) because of differences in biological mechanisms of drug disposition and pharmacological activity when compared with more established drug modalities
The 21st century vision for toxicity testing and risk assessment is to become more efficient at eval...
Animal studies testing medicinal herbs are often misinterpreted by both translational researchers an...
There is a growing body of evidence that the observed characteristics in pharmacokinetics and pharma...
Knowledge of the relationships among dose, drug concentration in blood, and clinical response is imp...
Since the human genome decoding, understanding and identification of genetic disturbances behind man...
<p>The predictions are derived by examining the formulas for these parameters as shown in <a href="h...
Cell and gene therapies have shown enormous promise across a range of diseases in recent years. Nume...
The aim of this work is to improve the current computational dosimetry approaches for in vitro and i...
In pharmaceutical drug development, information on where a drug distributes within the body is helpf...
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in ...
It is an FDA requirement that the “first in human ” dose be based on pre-clinical animal model effic...
We describe a comprehensive retrospective analysis in which the abilities of several methods by whic...
International audiencePredicting drug response is a challenging problem in oncology. In the 1975-198...
The use of transgenic animal models has transformed our knowledge of complex biochemical pathways in...
At the 2009 International Workshop on Genotoxicity Testing in Basel, an expert group gathered to pro...
The 21st century vision for toxicity testing and risk assessment is to become more efficient at eval...
Animal studies testing medicinal herbs are often misinterpreted by both translational researchers an...
There is a growing body of evidence that the observed characteristics in pharmacokinetics and pharma...
Knowledge of the relationships among dose, drug concentration in blood, and clinical response is imp...
Since the human genome decoding, understanding and identification of genetic disturbances behind man...
<p>The predictions are derived by examining the formulas for these parameters as shown in <a href="h...
Cell and gene therapies have shown enormous promise across a range of diseases in recent years. Nume...
The aim of this work is to improve the current computational dosimetry approaches for in vitro and i...
In pharmaceutical drug development, information on where a drug distributes within the body is helpf...
Like other cancer therapy agents under development, radionuclide therapies are usually evaluated in ...
It is an FDA requirement that the “first in human ” dose be based on pre-clinical animal model effic...
We describe a comprehensive retrospective analysis in which the abilities of several methods by whic...
International audiencePredicting drug response is a challenging problem in oncology. In the 1975-198...
The use of transgenic animal models has transformed our knowledge of complex biochemical pathways in...
At the 2009 International Workshop on Genotoxicity Testing in Basel, an expert group gathered to pro...
The 21st century vision for toxicity testing and risk assessment is to become more efficient at eval...
Animal studies testing medicinal herbs are often misinterpreted by both translational researchers an...
There is a growing body of evidence that the observed characteristics in pharmacokinetics and pharma...